These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31225921)

  • 1. Evaluation of Severe Myalgia Induced by Continuous-Infusion Bumetanide in Patients with Acute Heart Failure.
    Xiong L; Chinaeke EE; Lu K; Lenihan DJ; Merritt TE; Cox ZL
    Pharmacotherapy; 2019 Aug; 39(8):854-860. PubMed ID: 31225921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure.
    Ng TM; Konopka E; Hyderi AF; Hshieh S; Tsuji Y; Kim BJ; Han SY; Phan DH; Jeng AI; Lou M; Elkayam U
    J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):345-53. PubMed ID: 23538300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe musculoskeletal symptoms during continuous infusion of bumetanide.
    Howard PA; Dunn MI
    Chest; 1997 Feb; 111(2):359-64. PubMed ID: 9041982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with low-dose continuous infusion of furosemide in acute heart failure: assessment of efficacy and safety.
    Ng TM; Hshieh S; Chan CY; Elkayam U
    J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):373-81. PubMed ID: 22610091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure.
    Shah RV; McNulty S; O'Connor CM; Felker GM; Braunwald E; Givertz MM
    Am Heart J; 2012 Dec; 164(6):862-8. PubMed ID: 23194486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous moderate-dose bumetanide continuous infusion and severe musculoskeletal pain.
    Vaduganathan M; Allegretti AS; Manchette AM; Patel SS; Olson KR; Bazari H
    Int J Cardiol; 2013 Sep; 168(1):e29-31. PubMed ID: 23727101
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of adverse reactions to bumetanide and furosemide.
    Tuzel IH
    J Clin Pharmacol; 1981; 21(11):615-9. PubMed ID: 7338572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion.
    Dormans TP; van Meyel JJ; Gerlag PG; Tan Y; Russel FG; Smits P
    J Am Coll Cardiol; 1996 Aug; 28(2):376-82. PubMed ID: 8800113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion of furosemide combined with low-dose dopamine compared to intermittent boluses in acutely decompensated heart failure is less nephrotoxic and carries a lower readmission at thirty days.
    Aziz EF; Alviar CL; Herzog E; Cordova JP; Bastawrose JH; Pamidimukala CK; Tojino A; Park TS; Musat D; Kukin M
    Hellenic J Cardiol; 2011; 52(3):227-35. PubMed ID: 21642071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial.
    Palazzuoli A; Pellegrini M; Ruocco G; Martini G; Franci B; Campagna MS; Gilleman M; Nuti R; McCullough PA; Ronco C
    Crit Care; 2014 Jun; 18(3):R134. PubMed ID: 24974232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes of bumetanide continuous infusion: A systematic review and meta-analysis.
    Hansrivijit P; Techorueangwiwat C; Khanal R; Dimech CT; Thongprayoon C; Cheungpasitporn W
    Nephrology (Carlton); 2020 Oct; 25(10):744-748. PubMed ID: 32725702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal function on admission modifies prognostic impact of diuretics in acute heart failure: a propensity score matched and interaction analysis.
    Matsue Y; Shiraishi A; Kagiyama N; Yoshida K; Kume T; Okura H; Suzuki M; Matsumura A; Yoshida K; Hashimoto Y
    Heart Vessels; 2016 Dec; 31(12):1980-1987. PubMed ID: 26892531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP Trial.
    Sharma K; Vaishnav J; Kalathiya R; Hu JR; Miller J; Shah N; Hill T; Sharp M; Tsao A; Alexander KM; Gupta R; Montemayor K; Kovell L; Chasler JE; Lee YJ; Fine DM; Kass DA; Weiss RG; Thiemann DR; Ndumele CE; Schulman SP; Russell SD;
    JACC Heart Fail; 2018 Oct; 6(10):859-870. PubMed ID: 30098962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial.
    Triposkiadis FK; Butler J; Karayannis G; Starling RC; Filippatos G; Wolski K; Parissis J; Parisis C; Rovithis D; Koutrakis K; Skoularigis J; Antoniou CK; Chrysohoou C; Pitsavos C; Stefanadis C; Nastas J; Tsaknakis T; Mantziari L; Giannakoulas G; Karvounis H; Kalogeropoulos AP; Giamouzis G
    Int J Cardiol; 2014 Mar; 172(1):115-21. PubMed ID: 24485633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure.
    Aaser E; Gullestad L; Tølløfsrud S; Lundberg J; Hall C; Djøseland O; Kjekshus J; Forfang K
    Scand J Clin Lab Invest; 1997 Jul; 57(4):361-7. PubMed ID: 9249883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bumetanide--a new potent diuretic for oral and intravenous use].
    Johansson BW
    Lakartidningen; 1975 Sep; 72(37):3413-6. PubMed ID: 1099368
    [No Abstract]   [Full Text] [Related]  

  • 19. Syndrome of severe pain associated with a continuous bumetanide infusion.
    Shisler D; Austin TM; Delpire E; Sawyer DB; Pandey AK
    Int J Cardiol; 2014 Dec; 177(2):e61-2. PubMed ID: 25304072
    [No Abstract]   [Full Text] [Related]  

  • 20. A retrospective evaluation of the efficacy of intravenous bumetanide and comparison of potency with furosemide.
    Nappi JM
    Pharm Pract (Granada); 2013 Jan; 11(1):44-50. PubMed ID: 24155849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.